A critical component of our commitment to bring innovative therapies to patients
Phase 1 clinical trials are the first step in testing new treatments in people. These studies focus on safety, dosage, and how the body processes new drugs or therapies. They are essential for bringing innovative treatments to patients who may have limited options.
- Purpose: Assess safety, determine the best dose, and monitor side effects.
- Participants: Small groups (20–100), often patients with advanced conditions or healthy volunteers.
- Process: Participants are closely monitored in a controlled environment.
- Duration: Trials may last days, weeks, or longer, with required follow-up visits.
Get started
Find out if you’re eligible
Blood cancer trials
Review phase 1 clinical trials for blood cancers.
An open-label, phase 1b study of R289, an IRAK1/4 inhibitor, in patients with lower-risk myelodysplastic syndromes (LR MDS) who are relapsed/refractory/resistant to prior therapies.
A phase 1/2 multi-center study evaluating the safety and efficacy of IMPT-314, a CD19/20 bispecific chimeric antigen receptor (CAR) T Cell therapy in participants with relapsed or refractory aggressive B-Cell non-Hodgkin lymphoma.
A phase 3 randomized controlled trial of Rondecabtagene Autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-Cell product candidate, verses investigator’s choice of CD19 CAR T-Cell therapy in patients with relapsed or refractory large B-Cell Lymphoma in the second-line setting (PiNACLE-H2H).
Cancer (solid tumor) trials
Review phase 1 clinical trials for solid tumor cancers.
A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of the novel oral CDK2 DEGRADER NKT3964 in adults with advanced/metastatic solid tumors.
A phase 1, open-label, dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors.
A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of the novel oral CDK2 DEGRADER NKT3964 in adults with advanced/metastatic solid tumors.
A phase 1, open-label, dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors.
A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of the novel oral CDK2 DEGRADER NKT3964 in adults with advanced/metastatic solid tumors.
A phase 1, open-label, dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors.
A phase 1a/1b Study of 27T51, an anti-MUC16 CAR-T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer.
A phase 1, open-label, dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors.
A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of the novel oral CDK2 DEGRADER NKT3964 in adults with advanced/metastatic solid tumors.
A phase 1, open-label, dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors.
A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of the novel oral CDK2 DEGRADER NKT3964 in adults with advanced/metastatic solid tumors.
Autoimmune disease trials
Review phase 1 clinical trials for autoimmune diseases.
A phase 1 study evaluating the safety and preliminary efficacy of ALLO-329, a dual anti-CD19/anti-CD70 allogeneic CAR T Cell product in autoimmune disease.
A phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies.
A Phase 2, adaptive, randomized, open-label, assessor blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN).
A phase 1 study evaluating the safety and preliminary efficacy of ALLO-329, a dual anti-CD19/anti-CD70 allogeneic CAR T Cell product in autoimmune disease.
A phase 2, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis.
Benefits and risks of participating
While phase 1 trials may offer direct benefits benefits, they also carry risks. Here are some benefits and risks of participating in a phase 1 clinical trial for you to consider:
Benefits
- Early access to new treatments not available to the public.
- Personalized, attentive care from experienced medical professionals.
- Contribute to research and help future patients.
Risks
- Unknown side effects—these are the first human tests.
- No guaranteed benefit—the main goal is safety, not effectiveness.
- Time commitment—frequent visits and follow-ups may be required.
Frequently asked questions
Here are some common FAQs about phase 1 clinical trials.
- Phase 1: Safety and dosage (20–100 participants)
- Phase 2: Effectiveness and side effects (100–300 participants)
- Phase 3: Comparison to standard treatments (1,000–3,000 participants)
- Phase 4: Long-term monitoring after approval
Each trial has specific criteria. Our research team will guide you through the screening process.
If you have any other questions or concerns about phase 1 clinical trials, please email our research team.